Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Status:
Recruiting
Trial end date:
2028-01-10
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to compare sacituzumab tirumotecan to Treatment of
Physician's Choice (TPC) with respect to progression-free survival (PFS) per response
evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central
review (BICR), and overall survival (OS). The primary hypotheses are that sacituzumab
tirumotecan is superior to TPC with respect to PFS per RECIST 1.1, as assessed by BICR, and
that sacituzumab tirumotecan is superior to TPC with respect to OS.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborators:
European Network for Gynaecological Oncological Trial groups(ENGOT) GOG Foundation